Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Acupuncture in Macular Diseases (AMAD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02255981
Recruitment Status : Completed
First Posted : October 3, 2014
Results First Posted : April 1, 2020
Last Update Posted : June 16, 2020
Sponsor:
Information provided by (Responsible Party):
Dra. Luz Helena Gutiérrez C, Escuela Neijing

Brief Summary:
This is a single-arm study designed to assess the efficacy of acupuncture (Traditional Chinese Medicine) for chronic macular diseases of several types. All participants received acupuncture and massage and there is not a placebo group because it is not considered a good form to evaluate in Chinese Medicine due to, acupuncturing being a procedure is not as blind as is desired. As a control of the results in this trial, the outcomes could be contrasted against those reported in known medical publications and against expectations of the progress of the damage without treatment.

Condition or disease Intervention/treatment Phase
Age-related Macular Degeneration Stargardt Disease Macular Dystrophy Other: Acupuncture and massage Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Interventional, no randomized, no masking
Masking: None (Open Label)
Masking Description: Masking is neither accurate nor reliable in a procedure such as acupuncture or massage.
Primary Purpose: Treatment
Official Title: ¿Es Util la Acupuntura en la Degeneracion Macular? Prospective Study of Efficacy of Acupuncture in Macular Diseases
Study Start Date : March 2013
Actual Primary Completion Date : May 2016
Actual Study Completion Date : November 2016


Arm Intervention/treatment
Experimental: Acupuncture group

Acupuncture and massage Therapy of Traditional Chinese Medicine (acupuncture and Massage) for 24 months

.

Other: Acupuncture and massage

Treatment consists in to put needles on specific points of skin one day each week initially, then with longer spaces of time according to improvement.A total of 11 Chinese needles stainless steel, 25 x 40 were used by manual insertion and left for 12-15 minutes.

Periocular massage is taught and is practiced daily by the patient him or herself.

Other Names:
  • Traditional Chinese Medicine:( TCM)
  • acupuncture chinese style




Primary Outcome Measures :
  1. Change on Visual Acuity (VA) of the Treated Eyes From Baseline to the End of the Study [ Time Frame: Baseline, 2 months and every 2 months until month 24. ]

    The primary objective is to assess if acupuncture treatment is linked to a change in visual acuity (VA).

    VA was obtained by an ophthalmologic assessment at baseline and every two months until month 24. VA measurements were taken with the patient in a sitting position using a Snellen chart at a testing distance of 6 meters. The scale in Snellen is given in fractional numbers corresponding 20/20 to a normal vision at 20 ft or 6 meters. According to the World Health Organization, the normal vision is to 20/25, severe impairment corresponds to VA worse than 20/200 or legal blindness. Each fraction corresponds to a determined line of the chart in which all letters are correctly identified and the variation or gain is appreciated by the lines gained or lost by each eye.

    Improvement means a fraction better than initial, stable is no change in VA and lost is the VA worst than those of baseline.


  2. Eyes With Change From Baseline to the End of the Study in Distance Vision According to Categories CIE 10 Based on Lines Seen on the Snellen Chart. [ Time Frame: 24 months from baseline. ]
    Change in Visual Acuity was Measured by the Numbers of Lines seen on the Snellen Chart from baseline to the end of the trial. The measure was obtained by an ophthalmologic assessment on both eyes at the beginning of the study and every two months until month 24 using the best correction. VA measurements (lines in which all letters are correctly identified) were performed with the patient in a sitting position using a Snellen chart at a testing distance of 6 meters and the variation is appreciated by the lines gained or lost by each eye. The measure in Snellen is given in fractional numbers. Each fraction corresponds to a determined line of the chart corresponding VA 20/20 or 6/6 to a normal vision at 20 ft or 6 meters. The range of normal vision according to the WHO is to 20/25 ft or 6/10m, Mild means VA worse than 6/12, Moderate means VA worse than 6/18, Severe means VA worse than 6/60 that is "legal blindness". Blindness is considered VA worse than 3/60.

  3. Change From Baseline in the Number of Letters Seen on the Early Treatment Diabetic Retinopathy Study (ETDRS) Eye Chart [ Time Frame: Baseline and at end of study (up to 2 years) ]
    The ETDRS scale of letters is commonly used to report outcomes in AMD, for this reason, this score was chosen to compare outcomes with similar studies. Accepted tables for conversion from Snellen to ETDRS were used. 85 letters are equivalent to 20/20 and 0 letters correspond to 20/200. It can be meaningful to analyze the results in this trial in the context of similar trials using anti-VEGF, or reporting a visual loss in those cases that are not treatable.

  4. Number of Eyes That Improved VA From Baseline to End of the Study in Participants With Different Forms of Macular Disease Treated With Acupuncture. [ Time Frame: 2 years ]
    "Improved" was defined as cases that gained in visual acuity (Note: no minimum of letters was defined). "Stable" was defined as visual acuity did not change in the sense of not losing or gaining in the final identification of the optotypes. "Lost" was defined as patients who had a worse vision at the end than at the beginning (e.g., lost visual acuity because the disease continued its course and the treatment was not effective.)


Secondary Outcome Measures :
  1. Percentage of Participants Who Experienced Changes in Vision (Less Opacity, Less Distortion of Lines, Reduction of the Central Shadow) [ Time Frame: Baseline and end of study (up to 2 years) ]
    At study entry, major complaints of patients were collected by survey. Participants also completed a survey at the middle and at the end of the trial. This data is the percentage of participants that reported changes to the main visual complaints that they considered significant in their lives compared with the baseline.

  2. Number of Participants With Adverse Events Both Treatment-related or Not Related to Treatment. [ Time Frame: 2 years ]
    To report this measure the adverse events or risks had to be observed carefully and registered in order to care for the safety and to accomplish regulations of any treatment or medical intervention. For this procedure, the usual risks are some adverse events as moderate to severe pain, bleeding of more than a drop, ecchymosis bigger than 5 millimeters. Deaths and other serious events related or not with the therapeutic procedure, had to be reported.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • • Clinical diagnosis of Macular Disease.

    • The patient must accept treatment with acupuncture

Exclusion Criteria:

  • None

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02255981


Locations
Layout table for location information
Colombia
IPS Fundación Neijing
Guarne, Antioquia, Colombia, 0000
IPS Fundación Neijing
Medellin, Antioquia, Colombia, 0000
Sponsors and Collaborators
Escuela Neijing
Investigators
Layout table for investigator information
Principal Investigator: Luz H Gutierrez, MD, MPH Escuela Neijing Colombia
Study Director: Jose L Padilla, MD Hispano American Acupuncture Association-Beijing 84, Madrid, Spain
Study Chair: José R Gutiérrez, MD, Opht Sociedad Colombiana de Oftalmología
Study Chair: Libia V Ferrer, Tech TCM Escuela Neijing Colombia
Study Chair: Sergio L Pineda Escuela Neijing Colombia
Publications of Results:
Gutierrez L, Pineda S, Gutierrez R, Ferrer L. Acupuncture in Macular Diseases (AMAD) No published yet

Layout table for additonal information
Responsible Party: Dra. Luz Helena Gutiérrez C, Luz Gutierrez Physician, MPH, Escuela Neijing, Research Coordinator., Escuela Neijing
ClinicalTrials.gov Identifier: NCT02255981    
Other Study ID Numbers: Neijing Ophthalmology
First Posted: October 3, 2014    Key Record Dates
Results First Posted: April 1, 2020
Last Update Posted: June 16, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: sex, age, ophthalmologic diagnostic data (medical examination, images) diagnostic signs on Traditional Chinese Medicine (TCM), number of sessions, visual outcome, hazards, previous treatment. Individual participant data that underlie the results reported will be shared after deidentification
Supporting Materials: Clinical Study Report (CSR)
Time Frame: Inmediate following publication and no end term.
Access Criteria: Any

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Dra. Luz Helena Gutiérrez C, Escuela Neijing:
macular degeneration, acupuncture, OCT, Stargardt, dystrophy
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases